Only These Two Nifty Stocks Are Expected To Decline This Year
TCS and Sun Pharma are the two Nifty stocks expected to decline in 2018, Bloomberg data showed.
Only two stocks from NSE Nifty 50 Index are expected to decline in 2018, according to a consensus of analysts tracked by Bloomberg.
The estimated return potential suggests Tata Consultancy Services Ltd. and Sun Pharmaceutical Industries Ltd. are the two Nifty 50 stocks expected to give negative returns this year.
The country’s largest software services provider is expected to decline for the first time since 2004, by nearly 5 percent. That will be the biggest drop since 2015. The company’s key banking and financial services business has not completely recovered even as information technology spends improve as global growth returns. And the threat of U.S. curbs on visas for engineers sent by offshoring companies remains.
Shares of TCS returned 24.8 percent over the past 12 months, compared to 0.6 percent decline in the country’s benchmark Sensex.
Analysts expect Sun Pharma’s shares to fall by nearly 2 percent in the next 12 months—the first time since 2005. The drugmaker was weighed by its weaker forecast, Taro performance and a delay in drug filings from its key Halol plant amid U.S. sanctions.
Shares of Sun Pharma declined 16.1 percent in the last 12 months, compared to 15.1 percent decline in Nifty Pharma Index.
Aurobindo Pharma Ltd., Bharti Airtel Ltd. and UPL Ltd. are expected to gain the most in the next 12 months among the 50 stocks, Bloomberg data showed.